中文
Epitope in, antibody out: GeoFlow-V3 pushes the limit for efficient de novo antibody design
For the first time, GeoFlow V3 unifies generation, evaluation and in silico evolution of antibody binders, significantly improving their bind rates to 15.5%, 50x higher than SOTA methods in 2024.